Pulmonary Arterial Hypertension (PAH) Treatment Industry to Reach USD 7,224.4 Million by 2033 at a 2.2% of CAGR, Supported by Advancements in Therapies and Healthcare Accessibility

Pulmonary Arterial Hypertension (PAH) Treatment Industry
Pulmonary Arterial Hypertension (PAH) Treatment Industry

The global pulmonary arterial hypertension (PAH) treatment market is projected to grow from USD 5,811.5 million in 2023 to USD 7,224.4 million by 2033, expanding at a CAGR of 2.2% over the forecast period. The market’s steady growth is driven by increased awareness, improved accessibility to treatments, and the integration of complementary therapies alongside traditional pharmaceuticals.

Pulmonary arterial hypertension remains a challenging condition requiring a multidisciplinary approach. While pharmaceuticals dominate the treatment landscape, complementary therapies such as exercise programs, oxygen therapy, and nutritional support are gaining recognition for their role in enhancing patient outcomes.

Rising healthcare expenditures in developed economies have facilitated broader access to specialized PAH care and medications. Additionally, the growth of patient advocacy groups and support networks is driving awareness, encouraging research funding, and improving treatment adoption. Favorable healthcare reimbursement policies are also enabling more patients to access life-saving treatments, further propelling the market.

Get Full Report Now – https://www.futuremarketinsights.com/reports/pulmonary-arterial-hypertension-treatment-market

Key Market Trends and Highlights:

  1. Complementary Therapies: Exercise programs, oxygen therapy, and nutritional support are being integrated with traditional treatments, improving patient outcomes and quality of life.
  2. Healthcare Spending: Increased investments in healthcare systems, particularly in developed regions, are enhancing accessibility to advanced PAH therapies.
  3. Patient Advocacy: Growing influence of patient advocacy groups is raising awareness, driving research funding, and encouraging treatment adoption.
  4. Reimbursement Policies: Improvements in healthcare coverage are expanding access to PAH treatments, especially for underserved populations.

The PAH treatment market is positioned for sustained growth as advancements in therapies and healthcare infrastructure continue to improve accessibility and outcomes for patients globally.

Competitive Landscape

Collaborations between manufacturers, end-users, and research institutions can lead to the development of innovative pulmonary arterial hypertension treatment-based solutions for emerging applications.

The key strategies chosen by large companies include several growth strategies such as technology development, expansion as well and mergers and acquisitions to surge market share, reach and revenue.

  • In 2023, United Therapeutics Corporation announced the launch of its new PAH treatment, Tyvaso DPI (treprostinil). Tyvaso DPI is a dry powder inhaler formulation of treprostinil that is designed to improve the convenience and delivery of treprostinil treatment for PAH patients.
  • In 2023, Verfora Pharmaceuticals announced the initiation of a Phase 3 clinical trial of its new PAH treatment, VER-205. VER-205 is a novel oral PAH treatment that is designed to improve the efficacy and tolerability of PAH treatment.
  • In 2022, Bayer Pharmaceuticals announced the expansion of its clinical trial program for its PAH treatment, Adempas (riociguat). Bayer is conducting clinical trials to evaluate the use of Adempas in combination with other PAH treatments and to evaluate the use of Adempas in PAH patients with different comorbidities.
  • In 2022, Eli Lilly and Company announced the acquisition of Akros Therapeutics, a company that is developing new PAH treatments. The acquisition gives Lilly access to Akros Therapeutics’ portfolio of PAH treatments, including its lead drug candidate, AKR-001.

Key Companies Profiled

  • United Therapeutics Ltd.
  • Bayer AG
  • Actelion Ltd.
  • Pfizer, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Teva Pharmaceuticals Inc.
  • Eli Lilly and Company
  • Steady Med Ltd.
  • Johnson & Johnson Services, Inc.

Segmentation Analysis of the Pulmonary Arterial Hypertension Treatment Market

Drug Type:

  • Vasodilators
  • Phosphodiesterase 5 (PDE 5) Inhibitors
  • Endothelin Receptor Antagonists (ERA)
  • Soluble Guanylate Cyclase (SGC) Stimulator

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • South Asia & Pacific
  • East Asia
  • The Middle East & Africa

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

Leave a comment

Your email address will not be published. Required fields are marked *